NCT05428592尚未招募3 期
A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 Vaccine
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 1,100
- 试验地点
- 2
- 主要终点
- Seroconversion Rate (SCR) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)
研究概览
简要总结
This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18 years and older vaccinated 2 doses Inactivated SARS-CoV-2 Vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults aged 18 years and older.
- •Understand the contents of the ICF and voluntarily sign it (If the participant is unable to sign the ICF on his/her own due to illiteracy, an impartial witness is needed).
- •Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures.
- •Female participants of childbearing potential or partners of male participants: voluntarily agree to use effective contraception with their partners 14 days prior to the vaccination and must agree to continue such precautions during the study until 3 months after vaccination. [Effective contraception includes oral contraceptives, injectable or implantable contraception, extended-release topical contraceptives, hormonal patches, intrauterine devices (IUDs), sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.].
- •For female participants: without childbearing potential (amenorrhea for at least 1 year or documented surgical sterilization) or have used effective contraception with a negative pregnancy test before vaccination in this study.
- •Axillary temperature <37.3°C/99.1°F at screening visit and 72 hours prior to vaccination.
- •Healthy participants or participants with mild underlying disease [in a stable state without exacerbation (no admission to hospital or no major adjustment to treatment regimen, etc.) for at least 3 months prior to enrollment in this study].
- •Participants who have vaccinated 2 doses of CoronaVac® (with an interval of 3-8 weeks between 2 doses), for 6-12 months prior to enrollment.
排除标准
- •Previous medications intervention for the prophylaxis or prevention of COVID-19 (Including vaccination with any licensed SARS-CoV-2 vaccines other than 2 doses of CoronaVac® ).
- •History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) or other coronavirus infections.
- •History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-
- •History of allergy to any component of the study vaccine or history of severe allergic reaction to the vaccine or drug (including but not limited to anaphylaxis, allergic laryngeal oedema, anaphylactic purpura, thrombocytopenic purpura, or localized allergic necrosis (Arthus reaction)).
- •Positive nucleic acid for SARS-CoV-2 in nasopharyngeal/oropharyngeal swab specimens.
- •Positive HIV test result.
- •A history or family history of convulsions, epilepsy, encephalopathy and psychosis.
- •Malignant tumors in the active phase, malignant tumors not receiving adequate treatment, malignant tumors at potential risk of recurrence during the study period.
- •Congenital or functional splenic deficiency, complete or partial splenectomy for any reason.
- •Prolonged (defined as more than 14 days) use of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids, ≥20 mg/d prednisone or equivalent; however, inhaled and topical steroids are permitted) within 6 months prior to the vaccine.
- •Any other licensed vaccines given within 28 days prior to the study vaccination, or planned administration of vaccine(s) within 28 days after vaccination.
- •Have received immunoglobulin or other blood products within 3 months prior to enrollment or plan to receive them during the study period.
- •Blood donation or blood loss ≥ 450 mL within 1 month prior to enrolment, or planned donation during the study period.
- •Participants who have received any other investigational product within 1 month prior to enrollment or intent to participate in another clinical study at any time during the conduct of this study.
- •Female participants who are pregnant or breastfeeding.
- •Participants deemed unsuitable for participation in this study based on the investigator's assessment.
结局指标
主要结局
Seroconversion Rate (SCR) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)
时间窗: 14 days after vaccination for all participants
Seroconversion is defined as: GMT post vaccination≥ 4-fold rise from baseline GMT value
Geometric mean titer (GMT) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)
时间窗: 14 days after vaccination for all participants
Incidence of each solicited (local and systemic) AE and each unsolicited AE
时间窗: AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Duration of each solicited (local and systemic) AE and each unsolicited AE
时间窗: AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
Intensity of each solicited (local and systemic) AE and each unsolicited AE
时间窗: AE within 14 days, unsolicited AE within 28 days after vaccination for all participants
次要结局
- Causality of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events(within 12 months after vaccination for all participants)
- Geometric mean increase (GMI) of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)(14 days after vaccination for all participants)
- SCR of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)(28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- GMI of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- GMI of S-protein specific IgG antibodies (ELISA)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- GMT of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)(28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- SCR of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- Intensity of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events(within 12 months after vaccination for all participants)
- GMT of SARS-CoV-2 (Wild-type strain) VNA (pseudo-virus neutralizing assay)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- Incidence of serious adverse events (SAEs), adverse events of special interest (AESI), and the occurrence of pregnancy events(within 12 months after vaccination for all participants)
- GMI of SARS-CoV-2 (Wild-type strain) VNA (live virus neutralizing assay)(28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- GMT of S-protein specific IgG antibodies (ELISA)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
- SCR of S-protein specific IgG antibodies (ELISA)(14 days, 28 days, 3 months, 6 months, and 12 months after vaccination for all participants)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary ProceduresAnesthesia, DentalNCT00309335Novalar Pharmaceuticals, Inc.240
已完成
3 期
Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)InfertilityNCT02047227Merck KGaA, Darmstadt, Germany939
尚未招募
3 期
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Advanced Squamous Non-Small Cell Lung CarcinomaNCT05718167Chia Tai Tianqing Pharmaceutical Group Co., Ltd.570
撤回
3 期
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/BBotulismNCT01940315DynPort Vaccine Company LLC, A GDIT Company
已完成
3 期
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot UlcersFoot Ulcer, DiabeticInfectionNCT02447172Innocoll524